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Population dynamics of regulatory T cells (Treg) are crucial for the underlying interplay 
between leukemic and immune cells in progression of acute myeloid leukemia (AML). The goal of 
this work is to elucidate the dynamics of a model that includes Treg, which can be qualitatively 
assessed by accumulating clinical findings on the impact of activated immune cell infusion after 
selective Treg depletion. We constructed an ordinary differential equation model to describe the 
dynamics of three components in AML: leukemic blast cells, mature regulatory T cells (Treg), and 
mature effective T cells (Teff), including cytotoxic T lymphocytes. The model includes promotion of 
Treg expansion by leukemic blast cells, leukemic stem cell and progenitor cell targeting by Teff, and 
Treg-mediated Teff suppression, and exhibits two coexisting, stable steady states, corresponding to 
high leukemic cell load at diagnosis or relapse, and to long-term complete remission. Our model is 
capable of explaining the clinical findings that the survival of patients with AML after allogeneic 
stem cell transplantation is influenced by the duration of complete remission, and that cut-off 
minimal residual disease thresholds associated with a 100% relapse rate are identified in AML. 
 




Cancer progression occurs through the dynamical crosstalk between cancer cells and immune 
cells involved in both immunosurveillance and tumor-promoting inflammation. A better 
understanding of their co-evolutionary dynamics and the underlying mechanism is therefore critical 
for improved treatment outcomes. The leukemias represent unique models to assess the impact of 
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cancer on the host immune system as the cancer cells and immune cells originate from the same 
hematopoietic tissue and are in close proximity in peripheral blood and bone marrow. The initial 
treatment for acute myeloid leukemia (AML) is intensive induction chemotherapy, which aims to 
diminish leukemic cells and restore normal hematopoiesis, leading to complete remission (CR). 
Even though many patients achieve CR with induction and consolidation chemotherapy, the relapse 
rate is still high. Early or higher recovery of peripheral blood lymphocytes, neutrophils or platelets 
after cytotoxic chemotherapy are favorable prognostic factors for survival in patients with AML 
[1,2], suggesting the essential role of bone marrow reconstitution and recovered or enhanced anti-
leukemic activity in the inherent immune system.  
On the other hand, the regulatory T cell (Treg) is a contributing factor to suppression of anti-
leukemic activity [3]. While Tregs play a critical physiological role in immune tolerance to suppress 
excessive responses in allergy or autoimmunity [4,5] and to protect hematopoietic stem cells in bone 
marrow during inflammation [6], the immunosuppressive function of Tregs contributes to leukemia 
progression [6]. This has been supported by a growing body of evidence, which shows that lower 
frequency of Tregs at diagnosis is correlated with a higher rate of achieving CR [7], and that the 
frequency of Tregs in relapsed patients is dramatically higher [7], and that a high frequency of Tregs 
persists during CR [8-10].  
A number of mechanistic mathematical models [11-16] have been proposed to explain cell 
population dynamics and the effects of chemotherapy and targeted therapy against leukemia, and 
have been calibrated against time evolution data for leukemia obtained from patients. Some studies 
of mathematical modeling have focused on the impact of immune responses on leukemia 
progression during chemotherapy [17-19]. In this work, we constructed an ordinary differential 
equation model to describe the dynamics of three components in AML: leukemic blast cells (L), 
mature regulatory T cells (Treg), and mature effective T cells (Teff), including cytotoxic T 
lymphocytes (CTLs). Our modeling strategy arises from the assumption of dynamic equilibrium 
among leukemic cells and blood cells, even in relapsed AML, leading to the system having two 
discrete, alternative stable steady states, one corresponding to leukemic cell dominance and the other 
to negligible leukemic cell load. Experimental evidence for bistability has been provided in diverse 
biological systems, and positive-feedback loops or mutually inhibitory, double negative-feedback 
loops have been proposed as the underlying mechanisms [20-24]. With a given parameter set, our 
model exhibits two coexisting, stable steady states corresponding to high leukemic cell load at 
diagnosis or relapse, and to long-term complete remission, and the transition between two steady 
states during chemotherapy and immunotherapy is simulated and visualized by trajectories over time 
in three-dimensional (variable) space. Such viewpoints are based on a dynamical systems framework 
for resilience [25]. 
In this work, we have interpreted the transient dynamics of the system spending time before 
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returning to the state of high leukemic cell load as corresponding to transient CR before relapse. In 
addition, our mathematical model can explain the clinical findings that the survival of patients with 
AML after allogeneic stem cell transplantation is influenced by the duration of CR [26,27] and that 
cut-off minimal residual disease (MRD) thresholds associated with a 100% relapse rate are identified 
in AML [28]. 
 
2. Materials and Methods 
2.1 The model 
Our interest is in the dynamics that originate from the mechanism by which immune cells 
paradoxically contribute to leukemia progression. While a number of models have focused on cancer 
cells and cancer-specific cells such as CTLs, our motivation leads to the present model including 
Treg as the third player, which could be assessed by accumulating clinical findings on the impact of 
activated immune cell infusion with selective Treg depletion. 
Mature T cells, including CTLs and Tregs, are generated as a result of terminal differentiation 
in the hematopoietic hierarchy, in which hematopoietic stem cells (HSCs) at the top proliferate to 
give rise to progenitor cell types maintaining self-renewal ability. Leukemic stem cells (LSCs) and 
poorly differentiated leukemic progenitor cells with highly proliferative capability produce leukemic 
blast cells with resistance to apoptosis, leading to blast cell accumulation in peripheral blood [6]. In 
our model as illustrated in Fig. 1, we consider the populations of leukemic blast cells (L), mature 
regulatory T cells (Treg), and mature effective T cells (Teff), including CTLs. We assume that the 
dynamics of each cell population (L, Treg, Teff) are due to constant influx and first order decay by 
apoptosis, in which constant influx rates are denoted by aL, aTreg, and aTeff, and decay rate 
constants are denoted by dL, dTreg, and dTeff. In the model, the production of L results from the 
differentiation of LSCs and progenitor cells, and the production of Treg and Teff results from the 
differentiation of HSCs and progenitor cells. Together, aL, aTreg and aTeff are related to constant 
influxes from stem cells and progenitor cells collectively regarded as upstream cells. In addition, 
three intercellular interactions are identified as follows, and are modeled as Hill functions with 
threshold constants (k1, k2, k3) specifying the strength of intercellular interactions and the Hill 
coefficient p. 
1) Leukemic stem cell and progenitor cell targeting by CTLs: experimental evidence has suggested 
CTL-mediated elimination of LSCs in a situation with low levels of IFN-γ [29] and myeloid 
leukemic progenitor cell targeting by alloreactive CTLs [30], leading to aL modulation by [Teff]. 
2) Treg-mediated effector T cell suppression: inhibition of the proliferation and differentiation of 
effector T cells [31], and IL2-dependent inhibition of CTL differentiation [32] have been proposed as 
the mechanisms of Treg-mediated suppression of immune responses and hematopoiesis, leading to 
aTeff modulation by [Treg]. 
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3) Promotion of Treg formation by leukemic blast cells: The expression of PD-L1, indoleamine 2,3-
dioxygenase (IDO) and CD200, a type-1 transmembrane glycoprotein in leukemic blast cells, 
promotes formation of Tregs [3,33-35], leading to aTreg modulation by [L]. 
Since the model proposed here is to be primitively assessed by focusing on dynamics after 
hypothetical treatment, chemotherapy and immunotherapy were designed to shift the system from 
one point to another in three-variable space in a simple manner as follows. We assume that the 
concentrations of drugs are constant and the decay rate of each cell population (L, Treg, Teff) is 
proportional only to the cell population ([L], [Treg], [Teff]) during induction chemotherapy. The rate 
constants of decay due to apoptosis and drugs are accordingly combined together as dL, dTreg, and 
dTeff during chemotherapy. Hematopoietic cell transplantation (HCT) or CTL infusion and Treg 
targeting as immunotherapy was modeled by instantaneous increases and decreases in [Teff] and 
[Treg], respectively. 
The above model is translated into the following ordinary differential equations. 
 
                    1.1 
       1.2 
        1.3 
 
2.2 Parameter estimation and simulation 
Some parameters in Eq. (1) were estimated using Bayesian inference via a Markov chain 
Monte Carlo (MCMC) technique with clinical data for lymphocyte recovery after induction 
chemotherapy, which is described in the Results section below. We implemented PROC MCMC in 
SAS v.9.4 (SAS Institute, Cary, NC). PROC MCMC solved the ordinary differential equation 
defined in PROC FCMP and we used the resulting solution in the construction of the likelihood 
function. In MCMC PROC, the unknown parameters were modeled using random effects to account 
for time-series variability as follows: exp(β+α) where β denotes the fixed-effects parameter and α 
denotes the random-effects parameter with an unknown covariance matrix. Normal priors were used 
for β with N(0,10). The MCMC simulations were run for 20000 iterations and the first 1000 were 
considered burnin and removed.  
Steady states of the model were determined as the intersection of three nullclines (d[L]/dt = 0, 
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d[Teff]/dt = 0 and d[Treg]/dt = 0), which were numerically solved using the nleqslv R-package [36]. 
The ordinary differential equations in Eqs. 1.1, 1.2, and 1.3 were numerically solved using ODE 
solvers from MATLAB (Ver. 7.13; The Mathworks, Inc.).  
 
3. Results 
Using the MCMC technique, we parameterized the model using clinical data reported by 
Kanakry et al. [37]. They reported the kinetics of early lymphocyte recovery after intensive 
induction timed sequential therapy for AML and examined the immunophenotypic profile of the 
recovering lymphocytes. A median of 73% of the lymphocytes were CD3+ cells, which were 
composed of 16.7% CD3+CD4+ cells and 66.4% CD3+CD8+ cells. They reported that the median 
ratio of CD3+CD4+ cells to CD3+CD8+ cells was 2.7:1 and regulatory T cells characterized by 
CD3+CD4+ subpopulation expressing Foxp3 constituted 10.5% of CD3+CD4+ cells. We estimated 
cell numbers of regulatory T cells and CTLs characterized by CD3+CD8+ expression at each time 
point in the time course of lymphocyte recovery presented by Kanakry et al., with the assumption 
that the above immunophenotypic profile is not changed during early lymphocyte recovery after 
intensive chemotherapy.  
Assuming that [L] is approximately to be a constant [L]ss during complete remission (CR) 
after intensive induction chemotherapy, the model to be calibrated is Equations 1.2 and 1.3 with 
[L]ss. While < 5% leukemic blast cells among the total population of nucleated cells in bone marrow 
is included in the criteria for CR in AML, there is no definitive criterion for the peripheral blast 
count at CR. According to the clinical observation that 0% to 5% peripheral blast cells at CR had no 
effect on relapse free survival (RFS) time [38], we selected 100/μL for [L]ss during CR with 1% 
peripheral blast cells and 10000/μL as normal counts of peripheral nucleated cells.  
Estimated means and standard deviations of β for aTeff, aTreg, dTeff and dTreg by the MCMC 
method are 4.03±0.47, 5.29±1.08, -1.60±0.78 and -3.23±2.74, respectively. The time courses of 
[Teff] and [Treg] obtained by numerical integration of Equations 1.2 and 1.3 with aTeff=56.53, 
aTreg=198.2, dTeff=0.2 and dTreg=0.04 as exp(means) are shown in Fig. 2, together with counts of 
CD3+CD8+ cells (CTLs) and CD3+CD4+Foxp3+ cells (regulatory T cells) estimated from 
lymphocyte recovery after induction chemotherapy reported by Kanakry et al. [37].  
Dependencies of the steady-state concentrations of L, Teff, and Treg on the parameter k2, k3 
and p reveal two stable steady states corresponding to high and low concentrations accompanied by 
one unstable steady state with intermediate concentrations, as shown in Fig. 3. While keeping the 
parameters aTreg, aTeff, dTreg, and dTeff to estimated values by the MCMC method, we searched a 
wide range of the parameter space of aL, dL, k1 and found parameter ranges characterized by the 
existence of one or two stable steady states separated by an unstable fixed point. The values of k2, 
k3 and p were set within the parameter ranges of bistability. However, we cannot exclude the 
6 
 
existence of different dynamics, such as a limit cycle. The values of model parameters in the present 
study are listed in Table 1. 
We assume that the two stable steady states correspond to the state (SShi) of high leukemic 
cell load at diagnosis or relapse and the state (SSlo) of low leukemic cell load at long-term complete 
remission. In our simulations, the transitions from SShi to SSlo or the return to original SShi, which 
are induced by hypothetical chemotherapy and immunotherapy, were visualized as dynamical 
trajectories in three-dimensional space defined by the concentrations of L, Teff, and Treg.  
Fig. 4a shows the trajectories from SShi ([L], [Teff], [Treg] = 100000/μL, 0.00031/μL, 
4955/μL, out of figure) for chemotherapy with different values of dL. The locations of the state 
produced by chemotherapy shift toward SSlo ([L], [Teff], [Treg] = 40/μL, 283/μL, 8/μL) with 
increasing dL and determine whether the system reaches SSlo or returns to the original SShi. It is 
found that there are two basins of attraction in which the trajectories converge to SSlo and back to 
the original SShi. It is noted that the returning trajectories close to the boundary are attractive 
towards SSlo, compared with repulsive trajectories far from the boundary. Fig. 4b shows time 
courses corresponding to the returning trajectories. This indicates that the system spends 
considerable time in the vicinity of the boundary before returning to SShi. In Fig. 5, the state points 
leading to SShi are denoted by dots and those leading to SSlo are not marked, suggesting two basins 
of attraction. The latter can be seen as a blank region. It is noted that larger dots from which the 
system spends longer before returning to SShi are distributed along the boundary. We propose that 
transient CR with longer duration could be interpreted as having such transient dynamics [39] before 
returning to SShi, which could be considered in the framework of the resilience of dynamical 
systems [25]. 
There has been considerable interest in targeting Treg-mediated suppression of anti-AML 
reactive T cells. Bachanova et al. focused on the impact of prior Treg depletion followed by anti-
leukemic cell infusion [40]. Patients with refractory AML received Treg depletion with IL-2 
diphtheria toxin (IL2DT), which can selectively deplete IL-2 receptor-expressing cells, including 
Tregs. We simulated the impact of prior Treg depletion followed by Teff infusion. Teff infusion and 
Treg targeting were modeled by instantaneous modulations of [Teff] and [Treg] after hypothetical 
chemotherapy. An example is shown in Fig. 6. The returning trajectory to SShi after chemotherapy 
split into two trajectories. One is due to decreases in [Treg] followed by increases in [Teff] leading to 
SSlo. Another is due to only increases in [Teff], leading to the original SShi. The difference is due to 




The present model comprising L, Teff, and Treg, including promotion of Treg production by 
7 
 
L, exhibits two coexisting, stable steady states (SShi and SSlo) with a given parameter set. Assuming 
that SShi and SSlo correspond to the state at diagnosis or relapse and the state of long-term complete 
remission, the effects of hypothetical chemotherapy and immunotherapy inducing the transition from 
SShi to SSlo and returning to SShi are visualized as trajectories in three-dimensional space defined 
by L, Teff, and Treg concentrations.  
Our results demonstrate that there is, in three-dimensional space, a boundary between two 
basins of attraction of SShi and SSlo, and that effective treatments move the trajectory to the basin of 
attraction of SSlo. That is, given the existence of the boundary, the strategy of treatment design leads 
to how the trajectory from SShi is forced to exceed the boundary and reach the region in which all 
states begin their trajectories converging to SSlo. This viewpoint is in line with an ecological 
resilience perspective on cancer [41]. Some mathematical models of cancer and immune cells 
interplay exhibit multistable steady states and were used to investigate the effectiveness of state 
transitions between the basins of attraction by the combination of hypothetical immunotherapy with 
chemotherapy [42,43] or radiation therapy [44]. Our model, which incorporates positive feedback 
between regulatory T cells and leukemic cells, also shows bistability with two basins of attraction, 
which serve as a framework for assessing extensive studies of immunotherapy targeting regulatory T 
cells of immunosuppressive activity and design of combined immunotherapy with chemotherapy. 
The predictions that flow from the putative existence of the basin boundary are the effectiveness of 
Teff infusion/Treg depletion and the effect of the number of infused cells exceeding the boundary in 
three-dimensional space. These predictions remain to be evaluated by clinical studies of 
immunotherapy. 
The existence of the boundary suggested by this work may be supported by the findings of 
clinical studies of minimal residual disease (MRD) monitoring in leukemia. During CR attained with 
induction chemotherapy and maintenance treatment, submicroscopic amounts of residual leukemic 
cells in peripheral blood and bone marrow could not be identified cytomorphologically but could be 
sensitively detected by multiparameter flow cytometry (MFC) and quantitative real-time polymerase 
chain reaction (RT-qCR) in MRD monitoring [45,46]. Liu Yin et al. reported that RUNX1-
RUNX1T1 and CBFB-MYH11 fusion transcripts during CR in patients with core binding factor 
(CBF) positive AML were quantified by qPCR for bone marrow (BM) and peripheral blood (PB) 
samples [28]. They identified MRD thresholds predicting whether cytomorphologically-detectable 
hematologic relapse occurs: hematologic relapse was 100% in patients with more than 500 RUNX1-
RUNX1T1 copies in BM and more than 100 copies in PB, compared with 7% in patients with fewer 
than 500 copies and 7% in patients with fewer than 100 copies respectively, and 100% in patients 
with more than 50 CBFB-MYH11 copies in BM and 97% in patients with more than 10 copies in 
PB, compared with 10% in patients with fewer than 50 copies in BM and 7% in patients with fewer 
than 10 copies in PB respectively [28]. Several studies also reported MRD thresholds as independent 
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prognostic factors for predicting relapse occurrence in AML [47-49]. The MRD threshold can 
therefore be explained from the existence of the boundary found in our model.  
We propose that transient CR before relapse with longer duration corresponds to the case in 
which the system spends longer near the boundary before returning to SShi. This leads to the 
prediction that longer duration of CR achieved by induction and consolidation chemotherapy is a 
favorable factor for outcomes of the subsequent chemotherapy and HCT or infusion of purified 
effector cells at relapse, as lower-dose chemotherapy or lower load of effector cells is needed for the 
system located near the boundary to exceed it and converge to SSlo. Our prediction is in line with 
better outcomes achieved by chemotherapy [50,51] and HCT [52] for relapsing patients with longer 
duration of first CR. The distribution of CR duration could be simulated with a threshold defining 
CR and be translated to a relapse free survival (RFS) curve. The simulated RFS curves could be 
directly compared with clinical outcomes in treatments of AML, resulting in the validation of our 
model to predict the impact of chemotherapy and immunotherapy for AML.  
Another aspect of the trajectory crossing near the boundary is the accompanying transient 
increase in Teff concentration as shown in Fig. 4a. This leads to the prediction that higher absolute 
lymphocyte count (ALC) recovery is observed during CR with longer duration and is associated with 
a survival advantage for patients, which may be supported by ALC being identified as an 
independent prognostic factor for survival [53].  
With our viewpoint of transient CR corresponding to the trajectory returning to SShi in three-
dimensional space, relapse occurs without a change of parameter sets, in which coexisting stable 
steady states (SShi and SSlo) appear as shown in Fig. 3. On the other hand, assuming that the change 
of parameter values in our model is due to gene mutations during disease progression, the alternative 
explanation for relapse is possible. If the value of k2 decreases beyond the point of the bifurcation in 
Fig. 3a, the system remaining at SSlo is forced to go to SShi. 
In summary, the dynamics of this model qualitatively explain some clinical findings of AML. 
Our model, which is yet to be further assessed against clinical data, may provide valuable 
information for the future design of combined immunotherapy with chemotherapy in AML. 
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Fig. 1: Mechanistic model for crosstalk among leukemic cells and immune cells in AML. The 
processes of cell-cell interaction are numbered as follows: 1. Leukemic stem cells and progenitor 
cells targeted by effector T cells, 2. Effector T cell suppression mediated by Treg, and 3. Treg 









Fig. 2: Time courses of counts of CD3+CD8+ cells (CTLs, closed circles) and CD3+CD4+Foxp3+ 
cells (regulatory T cells, closed triangles) estimated from lymphocyte recovery after induction 
chemotherapy reported by Kanakry et al. [37]. Dashed lines show time courses of [Teff] and [Treg] 
obtained by numerical integration of Eqs 1.2 and 1.3 with aTeff=56.53, aTreg=198.2, dTeff=0.2 and 











Fig. 3: Steady states as a function of the threshold constant k2 of a) leukemic blast cells (L), b) 
mature effective T cells (Teff), and c) mature regulatory T cells (Treg), and of the threshold constant 
k3 of d) leukemic blast cells (L), and of the Hill coefficient p of e) leukemic blast cells (L). Steady 
states along the solid lines are stable and steady states along dashed lines are unstable. Parameter 
ranges characterized by the existence of two stable steady states separated by an unstable fixed point 
are marked by gray backgrounds. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, 
dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k3=200, and p=4 for a), b), c) ,and aL=1000, aTeff=56.53, 
aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, and p=4 for d), and aL=1000, 












































Fig. 4a: The trajectories from SShi (not shown in figure) after chemotherapy with different values of 
dL. The locations of the state produced by chemotherapy are denoted by closed circles. For higher 
dL, the trajectories with dL beyond a critical value change direction from returning to SShi to 
converging to SSlo, suggesting two basins of attraction. SShi ([L], [Teff], [Treg] = 100000/μL, 
0.00031/μL, 4955/μL, out of figure) and SSlo ([L], [Teff], [Treg] = 40/μL, 283/μL, 8/μL, open circle 
in figure) were calculated with dL=0.01. Other parameter values are aL=1000, aTeff=56.53, 
aTreg=198.2, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, and p=4. For a chemotherapy 
duration of 10 days, the decay rate constants were dTeff=0.8, dTreg=5.0, and dL was changed from 







Fig. 4b: Time courses corresponding to the trajectories returning to SShi. The start of relapse is 
delayed with increasing dL. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, 
dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, and p=4. For a chemotherapy duration of 10 days, 





Fig. 5: The basin of attraction of SShi. The size of each dot in the basin indicates the time required 
for the system to arrive at SShi from the state denoted by a dot. It takes longer for the system to 
arrive at SShi from states distributed along the basin boundary. Parameter values are aL=1000, 





Fig. 6: Effects of Teff infusion only and prior Treg depletion followed by Teff infusion for the system 
on the trajectory returning to SShi in hypothetical immunotherapy. The instantaneous modulations 
([Teff]+200/μl and [Treg]-5/μl) were applied at the point denoted by the blue circle. The Treg 
depletion forced the system from the point denoted by the blue circle to one denoted by the red 
circle. The same Teff infusions applied to the points denoted by blue and red circles result in two 
trajectories, one of which arrives at SSlo (open circle) and another returns to SShi (out of figure). 
Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, 
k2=160, k3=200, and p=4. For a chemotherapy duration of 10 days, the decay rate constants were 
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Population dynamics of regulatory T cells (Treg) are crucial for the underlying interplay 
between leukemic and immune cells in progression of acute myeloid leukemia (AML). The goal of 
this work is to elucidate the dynamics of a model that includes Treg, which can be qualitatively 
assessed by accumulating clinical findings on the impact of activated immune cell infusion after 
selective Treg depletion. We constructed an ordinary differential equation model to describe the 
dynamics of three components in AML: leukemic blast cells, mature regulatory T cells (Treg), and 
mature effective T cells (Teff), including cytotoxic T lymphocytes. The model includes promotion of 
Treg expansion by leukemic blast cells, leukemic stem cell and progenitor cell targeting by Teff, and 
Treg-mediated Teff suppression, and exhibits two coexisting, stable steady states, corresponding to 
high leukemic cell load at diagnosis or relapse, and to long-term complete remission. Our model is 
capable of explaining the clinical findings that the survival of patients with AML after allogeneic 
stem cell transplantation is influenced by the duration of complete remission, and that cut-off 
minimal residual disease thresholds associated with a 100% relapse rate are identified in AML. 
 




Cancer progression occurs through the dynamical crosstalk between cancer cells and immune 
cells involved in both immunosurveillance and tumor-promoting inflammation. A better 
understanding of their co-evolutionary dynamics and the underlying mechanism is therefore critical 
for improved treatment outcomes. The leukemias represent unique models to assess the impact of 
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cancer on the host immune system as the cancer cells and immune cells originate from the same 
hematopoietic tissue and are in close proximity in peripheral blood and bone marrow. The initial 
treatment for acute myeloid leukemia (AML) is intensive induction chemotherapy, which aims to 
diminish leukemic cells and restore normal hematopoiesis, leading to complete remission (CR). 
Even though many patients achieve CR with induction and consolidation chemotherapy, the relapse 
rate is still high. Early or higher recovery of peripheral blood lymphocytes, neutrophils or platelets 
after cytotoxic chemotherapy are favorable prognostic factors for survival in patients with AML 
[1,2], suggesting the essential role of bone marrow reconstitution and recovered or enhanced anti-
leukemic activity in the inherent immune system.  
On the other hand, the regulatory T cell (Treg) is a contributing factor to suppression of anti-
leukemic activity [3]. While Tregs play a critical physiological role in immune tolerance to suppress 
excessive responses in allergy or autoimmunity [4,5] and to protect hematopoietic stem cells in bone 
marrow during inflammation [6], the immunosuppressive function of Tregs contributes to leukemia 
progression [6]. This has been supported by a growing body of evidence, which shows that lower 
frequency of Tregs at diagnosis is correlated with a higher rate of achieving CR [7], and that the 
frequency of Tregs in relapsed patients is dramatically higher [7], and that a high frequency of Tregs 
persists during CR [8-10].  
A number of mechanistic mathematical models [11-16] have been proposed to explain cell 
population dynamics and the effects of chemotherapy and targeted therapy against leukemia, and 
have been calibrated against time evolution data for leukemia obtained from patients. Some studies 
of mathematical modeling have focused on the impact of immune responses on leukemia 
progression during chemotherapy [17-19]. In this work, we constructed an ordinary differential 
equation model to describe the dynamics of three components in AML: leukemic blast cells (L), 
mature regulatory T cells (Treg), and mature effective T cells (Teff), including cytotoxic T 
lymphocytes (CTLs). Our modeling strategy arises from the assumption of dynamic equilibrium 
among leukemic cells and blood cells, even in relapsed AML, leading to the system having two 
discrete, alternative stable steady states, one corresponding to leukemic cell dominance and the other 
to negligible leukemic cell load. Experimental evidence for bistability has been provided in diverse 
biological systems, and positive-feedback loops or mutually inhibitory, double negative-feedback 
loops have been proposed as the underlying mechanisms [20-24]. With a given parameter set, our 
model exhibits two coexisting, stable steady states corresponding to high leukemic cell load at 
diagnosis or relapse, and to long-term complete remission, and the transition between two steady 
states during chemotherapy and immunotherapy is simulated and visualized by trajectories over time 
in three-dimensional (variable) space. Such viewpoints are based on a dynamical systems framework 
for resilience [25]. 
In this work, we have interpreted the transient dynamics of the system spending time before 
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returning to the state of high leukemic cell load as corresponding to transient CR before relapse. In 
addition, our mathematical model can explain the clinical findings that the survival of patients with 
AML after allogeneic stem cell transplantation is influenced by the duration of CR [26,27] and that 
cut-off minimal residual disease (MRD) thresholds associated with a 100% relapse rate are identified 
in AML [28]. 
 
2. Materials and Methods 
2.1 The model 
Our interest is in the dynamics that originate from the mechanism by which immune cells 
paradoxically contribute to leukemia progression. While a number of models have focused on cancer 
cells and cancer-specific cells such as CTLs, our motivation leads to the present model including 
Treg as the third player, which could be assessed by accumulating clinical findings on the impact of 
activated immune cell infusion with selective Treg depletion. 
Mature T cells, including CTLs and Tregs, are generated as a result of terminal differentiation 
in the hematopoietic hierarchy, in which hematopoietic stem cells (HSCs) at the top proliferate to 
give rise to progenitor cell types maintaining self-renewal ability. Leukemic stem cells (LSCs) and 
poorly differentiated leukemic progenitor cells with highly proliferative capability produce leukemic 
blast cells with resistance to apoptosis, leading to blast cell accumulation in peripheral blood [6]. In 
our model as illustrated in Fig. 1, we consider the populations of leukemic blast cells (L), mature 
regulatory T cells (Treg), and mature effective T cells (Teff), including CTLs. We assume that the 
dynamics of each cell population (L, Treg, Teff) are due to constant influx and first order decay by 
apoptosis, in which constant influx rates are denoted by aL, aTreg, and aTeff, and decay rate 
constants are denoted by dL, dTreg, and dTeff. In the model, the production of L results from the 
differentiation of LSCs and progenitor cells, and the production of Treg and Teff results from the 
differentiation of HSCs and progenitor cells. Together, aL, aTreg and aTeff are related to constant 
influxes from stem cells and progenitor cells collectively regarded as upstream cells. In addition, 
three intercellular interactions are identified as follows, and are modeled as Hill functions with 
threshold constants (k1, k2, k3) specifying the strength of intercellular interactions and the Hill 
coefficient p. 
1) Leukemic stem cell and progenitor cell targeting by CTLs: experimental evidence has suggested 
CTL-mediated elimination of LSCs in a situation with low levels of IFN-γ [29] and myeloid 
leukemic progenitor cell targeting by alloreactive CTLs [30], leading to aL modulation by [Teff]. 
2) Treg-mediated effector T cell suppression: inhibition of the proliferation and differentiation of 
effector T cells [31], and IL2-dependent inhibition of CTL differentiation [32] have been proposed as 
the mechanisms of Treg-mediated suppression of immune responses and hematopoiesis, leading to 
aTeff modulation by [Treg]. 
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3) Promotion of Treg formation by leukemic blast cells: The expression of PD-L1, indoleamine 2,3-
dioxygenase (IDO) and CD200, a type-1 transmembrane glycoprotein in leukemic blast cells, 
promotes formation of Tregs [3,33-35], leading to aTreg modulation by [L]. 
Since the model proposed here is to be primitively assessed by focusing on dynamics after 
hypothetical treatment, chemotherapy and immunotherapy were designed to shift the system from 
one point to another in three-variable space in a simple manner as follows. We assume that the 
concentrations of drugs are constant and the decay rate of each cell population (L, Treg, Teff) is 
proportional only to the cell population ([L], [Treg], [Teff]) during induction chemotherapy. The rate 
constants of decay due to apoptosis and drugs are accordingly combined together as dL, dTreg, and 
dTeff during chemotherapy. Hematopoietic cell transplantation (HCT) or CTL infusion and Treg 
targeting as immunotherapy was modeled by instantaneous increases and decreases in [Teff] and 
[Treg], respectively. 
The above model is translated into the following ordinary differential equations. 
 
                    1.1 
       1.2 
        1.3 
 
2.2 Parameter estimation and simulation 
Some parameters in Eq. (1) were estimated using Bayesian inference via a Markov chain 
Monte Carlo (MCMC) technique with clinical data for lymphocyte recovery after induction 
chemotherapy, which is described in the Results section below. We implemented PROC MCMC in 
SAS v.9.4 (SAS Institute, Cary, NC). PROC MCMC solved the ordinary differential equation 
defined in PROC FCMP and we used the resulting solution in the construction of the likelihood 
function. In MCMC PROC, the unknown parameters were modeled using random effects to account 
for time-series variability as follows: exp(β+α) where β denotes the fixed-effects parameter and α 
denotes the random-effects parameter with an unknown covariance matrix. Normal priors were used 
for β with N(0,10). The MCMC simulations were run for 20000 iterations and the first 1000 were 
considered burnin and removed.  
Steady states of the model were determined as the intersection of three nullclines (d[L]/dt = 0, 
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d[Teff]/dt = 0 and d[Treg]/dt = 0), which were numerically solved using the nleqslv R-package [36]. 
The ordinary differential equations in Eqs. 1.1, 1.2, and 1.3 were numerically solved using ODE 
solvers from MATLAB (Ver. 7.13; The Mathworks, Inc.).  
 
3. Results 
Using the MCMC technique, we parameterized the model using clinical data reported by 
Kanakry et al. [37]. They reported the kinetics of early lymphocyte recovery after intensive 
induction timed sequential therapy for AML and examined the immunophenotypic profile of the 
recovering lymphocytes. A median of 73% of the lymphocytes were CD3+ cells, which were 
composed of 16.7% CD3+CD4+ cells and 66.4% CD3+CD8+ cells. They reported that the median 
ratio of CD3+CD4+ cells to CD3+CD8+ cells was 2.7:1 and regulatory T cells characterized by 
CD3+CD4+ subpopulation expressing Foxp3 constituted 10.5% of CD3+CD4+ cells. We estimated 
cell numbers of regulatory T cells and CTLs characterized by CD3+CD8+ expression at each time 
point in the time course of lymphocyte recovery presented by Kanakry et al., with the assumption 
that the above immunophenotypic profile is not changed during early lymphocyte recovery after 
intensive chemotherapy.  
Assuming that [L] is approximately to be a constant [L]ss during complete remission (CR) 
after intensive induction chemotherapy, the model to be calibrated is Equations 1.2 and 1.3 with 
[L]ss. While < 5% leukemic blast cells among the total population of nucleated cells in bone marrow 
is included in the criteria for CR in AML, there is no definitive criterion for the peripheral blast 
count at CR. According to the clinical observation that 0% to 5% peripheral blast cells at CR had no 
effect on relapse free survival (RFS) time [38], we selected 100/μL for [L]ss during CR with 1% 
peripheral blast cells and 10000/μL as normal counts of peripheral nucleated cells.  
Estimated means and standard deviations of β for aTeff, aTreg, dTeff and dTreg by the MCMC 
method are 4.03±0.47, 5.29±1.08, -1.60±0.78 and -3.23±2.74, respectively. The time courses of 
[Teff] and [Treg] obtained by numerical integration of Equations 1.2 and 1.3 with aTeff=56.53, 
aTreg=198.2, dTeff=0.2 and dTreg=0.04 as exp(means) are shown in Fig. 2, together with counts of 
CD3+CD8+ cells (CTLs) and CD3+CD4+Foxp3+ cells (regulatory T cells) estimated from 
lymphocyte recovery after induction chemotherapy reported by Kanakry et al. [37].  
Dependencies of the steady-state concentrations of L, Teff, and Treg on the parameter k2, k3 
and p reveal two stable steady states corresponding to high and low concentrations accompanied by 
one unstable steady state with intermediate concentrations, as shown in Fig. 3. While keeping the 
parameters aTreg, aTeff, dTreg, and dTeff to estimated values by the MCMC method, we searched a 
wide range of the parameter space of aL, dL, k1 and found parameter ranges characterized by the 
existence of one or two stable steady states separated by an unstable fixed point. The values of k2, 
k3 and p were set within the parameter ranges of bistability. However, we cannot exclude the 
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existence of different dynamics, such as a limit cycle. The values of model parameters in the present 
study are listed in Table 1. 
We assume that the two stable steady states correspond to the state (SShi) of high leukemic 
cell load at diagnosis or relapse and the state (SSlo) of low leukemic cell load at long-term complete 
remission. In our simulations, the transitions from SShi to SSlo or the return to original SShi, which 
are induced by hypothetical chemotherapy and immunotherapy, were visualized as dynamical 
trajectories in three-dimensional space defined by the concentrations of L, Teff, and Treg.  
Fig. 4a shows the trajectories from SShi ([L], [Teff], [Treg] = 100000/μL, 0.00031/μL, 
4955/μL, out of figure) for chemotherapy with different values of dL. The locations of the state 
produced by chemotherapy shift toward SSlo ([L], [Teff], [Treg] = 40/μL, 283/μL, 8/μL) with 
increasing dL and determine whether the system reaches SSlo or returns to the original SShi. It is 
found that there are two basins of attraction in which the trajectories converge to SSlo and back to 
the original SShi. It is noted that the returning trajectories close to the boundary are attractive 
towards SSlo, compared with repulsive trajectories far from the boundary. Fig. 4b shows time 
courses corresponding to the returning trajectories. This indicates that the system spends 
considerable time in the vicinity of the boundary before returning to SShi. In Fig. 5, the state points 
leading to SShi are denoted by dots and those leading to SSlo are not marked, suggesting two basins 
of attraction. The latter can be seen as a blank region. It is noted that larger dots from which the 
system spends longer before returning to SShi are distributed along the boundary. We propose that 
transient CR with longer duration could be interpreted as having such transient dynamics [39] before 
returning to SShi, which could be considered in the framework of the resilience of dynamical 
systems [25]. 
There has been considerable interest in targeting Treg-mediated suppression of anti-AML 
reactive T cells. Bachanova et al. focused on the impact of prior Treg depletion followed by anti-
leukemic cell infusion [40]. Patients with refractory AML received Treg depletion with IL-2 
diphtheria toxin (IL2DT), which can selectively deplete IL-2 receptor-expressing cells, including 
Tregs. We simulated the impact of prior Treg depletion followed by Teff infusion. Teff infusion and 
Treg targeting were modeled by instantaneous modulations of [Teff] and [Treg] after hypothetical 
chemotherapy. An example is shown in Fig. 6. The returning trajectory to SShi after chemotherapy 
split into two trajectories. One is due to decreases in [Treg] followed by increases in [Teff] leading to 
SSlo. Another is due to only increases in [Teff], leading to the original SShi. The difference is due to 




The present model comprising L, Teff, and Treg, including promotion of Treg production by 
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L, exhibits two coexisting, stable steady states (SShi and SSlo) with a given parameter set. Assuming 
that SShi and SSlo correspond to the state at diagnosis or relapse and the state of long-term complete 
remission, the effects of hypothetical chemotherapy and immunotherapy inducing the transition from 
SShi to SSlo and returning to SShi are visualized as trajectories in three-dimensional space defined 
by L, Teff, and Treg concentrations.  
Our results demonstrate that there is, in three-dimensional space, a boundary between two 
basins of attraction of SShi and SSlo, and that effective treatments move the trajectory to the basin of 
attraction of SSlo. That is, given the existence of the boundary, the strategy of treatment design leads 
to how the trajectory from SShi is forced to exceed the boundary and reach the region in which all 
states begin their trajectories converging to SSlo. This viewpoint is in line with an ecological 
resilience perspective on cancer [41]. Some mathematical models of cancer and immune cells 
interplay exhibit multistable steady states and were used to investigate the effectiveness of state 
transitions between the basins of attraction by the combination of hypothetical immunotherapy with 
chemotherapy [42,43] or radiation therapy [44]. Our model, which incorporates positive feedback 
between regulatory T cells and leukemic cells, also shows bistability with two basins of attraction, 
which serve as a framework for assessing extensive studies of immunotherapy targeting regulatory T 
cells of immunosuppressive activity and design of combined immunotherapy with chemotherapy. 
The predictions that flow from the putative existence of the basin boundary are the effectiveness of 
Teff infusion/Treg depletion and the effect of the number of infused cells exceeding the boundary in 
three-dimensional space. These predictions remain to be evaluated by clinical studies of 
immunotherapy. 
The existence of the boundary suggested by this work may be supported by the findings of 
clinical studies of minimal residual disease (MRD) monitoring in leukemia. During CR attained with 
induction chemotherapy and maintenance treatment, submicroscopic amounts of residual leukemic 
cells in peripheral blood and bone marrow could not be identified cytomorphologically but could be 
sensitively detected by multiparameter flow cytometry (MFC) and quantitative real-time polymerase 
chain reaction (RT-qCR) in MRD monitoring [45,46]. Liu Yin et al. reported that RUNX1-
RUNX1T1 and CBFB-MYH11 fusion transcripts during CR in patients with core binding factor 
(CBF) positive AML were quantified by qPCR for bone marrow (BM) and peripheral blood (PB) 
samples [28]. They identified MRD thresholds predicting whether cytomorphologically-detectable 
hematologic relapse occurs: hematologic relapse was 100% in patients with more than 500 RUNX1-
RUNX1T1 copies in BM and more than 100 copies in PB, compared with 7% in patients with fewer 
than 500 copies and 7% in patients with fewer than 100 copies respectively, and 100% in patients 
with more than 50 CBFB-MYH11 copies in BM and 97% in patients with more than 10 copies in 
PB, compared with 10% in patients with fewer than 50 copies in BM and 7% in patients with fewer 
than 10 copies in PB respectively [28]. Several studies also reported MRD thresholds as independent 
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prognostic factors for predicting relapse occurrence in AML [47-49]. The MRD threshold can 
therefore be explained from the existence of the boundary found in our model.  
We propose that transient CR before relapse with longer duration corresponds to the case in 
which the system spends longer near the boundary before returning to SShi. This leads to the 
prediction that longer duration of CR achieved by induction and consolidation chemotherapy is a 
favorable factor for outcomes of the subsequent chemotherapy and HCT or infusion of purified 
effector cells at relapse, as lower-dose chemotherapy or lower load of effector cells is needed for the 
system located near the boundary to exceed it and converge to SSlo. Our prediction is in line with 
better outcomes achieved by chemotherapy [50,51] and HCT [52] for relapsing patients with longer 
duration of first CR. The distribution of CR duration could be simulated with a threshold defining 
CR and be translated to a relapse free survival (RFS) curve. The simulated RFS curves could be 
directly compared with clinical outcomes in treatments of AML, resulting in the validation of our 
model to predict the impact of chemotherapy and immunotherapy for AML.  
Another aspect of the trajectory crossing near the boundary is the accompanying transient 
increase in Teff concentration as shown in Fig. 4a. This leads to the prediction that higher absolute 
lymphocyte count (ALC) recovery is observed during CR with longer duration and is associated with 
a survival advantage for patients, which may be supported by ALC being identified as an 
independent prognostic factor for survival [53].  
With our viewpoint of transient CR corresponding to the trajectory returning to SShi in three-
dimensional space, relapse occurs without a change of parameter sets, in which coexisting stable 
steady states (SShi and SSlo) appear as shown in Fig. 3. On the other hand, assuming that the change 
of parameter values in our model is due to gene mutations during disease progression, the alternative 
explanation for relapse is possible. If the value of k2 decreases beyond the point of the bifurcation in 
Fig. 3a, the system remaining at SSlo is forced to go to SShi. 
In summary, the dynamics of this model qualitatively explain some clinical findings of AML. 
Our model, which is yet to be further assessed against clinical data, may provide valuable 
information for the future design of combined immunotherapy with chemotherapy in AML. 
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Fig. 1: Mechanistic model for crosstalk among leukemic cells and immune cells in AML. The 
processes of cell-cell interaction are numbered as follows: 1. Leukemic stem cells and progenitor 
cells targeted by effector T cells, 2. Effector T cell suppression mediated by Treg, and 3. Treg 









Fig. 2: Time courses of counts of CD3+CD8+ cells (CTLs, closed circles) and CD3+CD4+Foxp3+ 
cells (regulatory T cells, closed triangles) estimated from lymphocyte recovery after induction 
chemotherapy reported by Kanakry et al. [37]. Dashed lines show time courses of [Teff] and [Treg] 
obtained by numerical integration of Eqs 1.2 and 1.3 with aTeff=56.53, aTreg=198.2, dTeff=0.2 and 











Fig. 3: Steady states as a function of the threshold constant k2 of a) leukemic blast cells (L), b) 
mature effective T cells (Teff), and c) mature regulatory T cells (Treg), and of the threshold constant 
k3 of d) leukemic blast cells (L), and of the Hill coefficient p of e) leukemic blast cells (L). Steady 
states along the solid lines are stable and steady states along dashed lines are unstable. Parameter 
ranges characterized by the existence of two stable steady states separated by an unstable fixed point 
are marked by gray backgrounds. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, 
dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k3=200, and p=4 for a), b), c) ,and aL=1000, aTeff=56.53, 
aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, and p=4 for d), and aL=1000, 












































Fig. 4a: The trajectories from SShi (not shown in figure) after chemotherapy with different values of 
dL. The locations of the state produced by chemotherapy are denoted by closed circles. For higher 
dL, the trajectories with dL beyond a critical value change direction from returning to SShi to 
converging to SSlo, suggesting two basins of attraction. SShi ([L], [Teff], [Treg] = 100000/μL, 
0.00031/μL, 4955/μL, out of figure) and SSlo ([L], [Teff], [Treg] = 40/μL, 283/μL, 8/μL, open circle 
in figure) were calculated with dL=0.01. Other parameter values are aL=1000, aTeff=56.53, 
aTreg=198.2, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, and p=4. For a chemotherapy 
duration of 10 days, the decay rate constants were dTeff=0.8, dTreg=5.0, and dL was changed from 







Fig. 4b: Time courses corresponding to the trajectories returning to SShi. The start of relapse is 
delayed with increasing dL. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, 
dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, and p=4. For a chemotherapy duration of 10 days, 





Fig. 5: The basin of attraction of SShi. The size of each dot in the basin indicates the time required 
for the system to arrive at SShi from the state denoted by a dot. It takes longer for the system to 
arrive at SShi from states distributed along the basin boundary. Parameter values are aL=1000, 





Fig. 6: Effects of Teff infusion only and prior Treg depletion followed by Teff infusion for the system 
on the trajectory returning to SShi in hypothetical immunotherapy. The instantaneous modulations 
([Teff]+200/μl and [Treg]-5/μl) were applied at the point denoted by the blue circle. The Treg 
depletion forced the system from the point denoted by the blue circle to one denoted by the red 
circle. The same Teff infusions applied to the points denoted by blue and red circles result in two 
trajectories, one of which arrives at SSlo (open circle) and another returns to SShi (out of figure). 
Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, 
k2=160, k3=200, and p=4. For a chemotherapy duration of 10 days, the decay rate constants were 
dL=1.0, dTeff=0.7, and dTreg=5.0. 
 
